NCT07246863 2026-03-04
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
CatalYm GmbH
Mirati Therapeutics Inc.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Nanjing Leads Biolabs Co.,Ltd
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Gilead Sciences
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shin Kong Wu Ho-Su Memorial Hospital
Eli Lilly and Company
National University Hospital, Singapore